603590 Stock Overview
Engages in the research and development, production, and sale of pharmaceuticals in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Beijing Konruns Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥24.35 |
| 52 Week High | CN¥41.95 |
| 52 Week Low | CN¥20.07 |
| Beta | 0.43 |
| 11 Month Change | 1.08% |
| 3 Month Change | 3.09% |
| 1 Year Change | -40.46% |
| 33 Year Change | -23.23% |
| 5 Year Change | -28.88% |
| Change since IPO | -30.53% |
Recent News & Updates
Beijing Konruns Pharmaceutical Co.,Ltd.'s (SHSE:603590) Shares Not Telling The Full Story
Sep 29
Concerns Surrounding Beijing Konruns PharmaceuticalLtd's (SHSE:603590) Performance
Sep 03Shareholder Returns
| 603590 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 1.5% | -1.5% | -2.1% |
| 1Y | -40.5% | -9.4% | 2.8% |
Return vs Industry: 603590 underperformed the CN Pharmaceuticals industry which returned -9.4% over the past year.
Return vs Market: 603590 underperformed the CN Market which returned 2.8% over the past year.
Price Volatility
| 603590 volatility | |
|---|---|
| 603590 Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 603590 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 603590's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 447 | n/a | www.konruns.cn |
Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations.
Beijing Konruns Pharmaceutical Co.,Ltd. Fundamentals Summary
| 603590 fundamental statistics | |
|---|---|
| Market cap | CN¥3.81b |
| Earnings (TTM) | CN¥114.79m |
| Revenue (TTM) | CN¥846.29m |
33.7x
P/E Ratio4.6x
P/S RatioIs 603590 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603590 income statement (TTM) | |
|---|---|
| Revenue | CN¥846.29m |
| Cost of Revenue | CN¥96.53m |
| Gross Profit | CN¥749.75m |
| Other Expenses | CN¥634.96m |
| Earnings | CN¥114.79m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.72 |
| Gross Margin | 88.59% |
| Net Profit Margin | 13.56% |
| Debt/Equity Ratio | 5.8% |
How did 603590 perform over the long term?
See historical performance and comparison